What is Hillstream BioPharma, Inc. (HILS) stock price today?

Hillstream BioPharma, Inc. (HILS) is currently trading at $0.24, up 5.66% today.

What is HILS P/E ratio?

Hillstream BioPharma, Inc.'s P/E ratio is -0.66. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HILS return on equity (ROE)?

Hillstream BioPharma, Inc.'s return on equity (ROE) is -36.93%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Hillstream BioPharma, Inc.'s market cap?

Hillstream BioPharma, Inc. has a market capitalization of $4.17M.

NASDAQ · Biotechnology

Hillstream BioPharma, Inc. (HILS) Stock

$0.24 +5.66% NASDAQ: HILS Healthcare

Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options.

Valuation

Metric	Value
Price	$0.24
Market Cap	$4.17M
P/E Ratio	-0.66
P/B Ratio	0.10
P/S Ratio	0.00
EPS (TTM)	$-1.12
52-Week High	$2.65
52-Week Low	$0.17
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-36.93%
ROA	-13.81%
ROCE	-9.33%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	37.75

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-3.0M	$-7.0M	$-9.0M	$-12.0M	$-20.0M
Net Profit	$-3.0M	$-8.0M	$-9.0M	$-12.0M	$-36.0M
EPS	$-0.30	$-0.75	$-7.14	$-9.41	$-1.12
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.0M	$7.0M	$11.0M	$4.0M	$519.0M
Total Liabilities	$5.0M	$1.0M	$2.0M	$2.0M	$121.0M
Cash	$0	$7.0M	$11.0M	$4.0M	$17.0M
Borrowings	$2.0M	$0	$0	$0	$0

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$-7.0M	$-7.0M	$-11.0M	$-16.0M
Investing Cash Flow	$0	$0	$0	$0	$-78.0M
Financing Cash Flow	$1.0M	$13.0M	$12.0M	$4.0M	$107.0M
Net Cash Flow	$0	$7.0M	$4.0M	$-7.0M	$13.0M
Free Cash Flow	$-1.0M	$-7.0M	$-7.0M	$-11.0M	$-16.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.69
FCF Yield	-505.16%
Quick Ratio	37.75
Interest Coverage	-4634.51
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
APTOAptose Biosciences Inc.	$1.71	+100.00%	-0.16	$4.36M	0.00%
BCELAtreca, Inc.	$0.09	-1.32%	-0.04	$3.57M	0.00%
CYTOAltamira Therapeutics Ltd.	$0.30	+100.00%	-0.02	$1.13M	0.00%
GMDAGamida Cell Ltd.	$0.03	+0.00%	-0.08	$4.34M	0.00%
GRTSGritstone bio, Inc.	$0.03	-31.78%	-0.03	$3.80M	0.00%

About Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.

Hillstream BioPharma, Inc. is headquartered in US.

Hillstream BioPharma, Inc. (HILS) stock trades at $0.24 with a market capitalization of $4.17M. The stock is valued at a price-to-earnings (P/E) ratio of -0.66, price-to-book of 0.10, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.17 and $2.65, and currently trades 90.9% below its 52-week high.

On profitability, Hillstream BioPharma, Inc. generates a return on equity (ROE) of -36.93%, return on capital employed of -9.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.hillstreambio.com